Tumor-agnostic genomic and clinical analysis of solid tumors with BRAF fusions

被引：0
|
作者：
Chen, Monica F.
Yang, Soo-Ryum
Tao, Jessica
Desilets, Antoine
Rosen, Ezra
Gong, Yixuan
Mullaney, Kerry A.
Kris, Mark G.
Arcila, Maria E.
Donoghue, Mark
Somwar, Romel
Ladanyi, Marc
Rosen, Neal
Yaeger, Rona
Drilon, Alexander E.
Offin, Michael
Murciano-Goroff, Yonina R.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[3] CHUM, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3146
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
    Chen, Monica F.
    Yang, Soo-Ryum
    Tao, Jessica J.
    Desilets, Antoine
    Diamond, Eli L.
    Wilhelm, Clare
    Rosen, Ezra
    Gong, Yixiao
    Mullaney, Kerry
    Torrisi, Jean
    Young, Robert J.
    Somwar, Romel
    Yu, Helena A.
    Kris, Mark G.
    Riely, Gregory J.
    Arcila, Maria E.
    Ladanyi, Marc
    Donoghue, Mark T. A.
    Rosen, Neal
    Yaeger, Rona
    Drilon, Alexander
    Murciano-Goroff, Yonina R.
    Offin, Michael
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3812 - 3823
  • [2] Are FGFR Fusions and Mutations the Next Tumor-Agnostic Targets in Oncology?
    Ellis, Haley
    Goyal, Lipika
    JCO PRECISION ONCOLOGY, 2024, 8
  • [3] Tumor-agnostic drug development in dMMR/MSI-H solid tumors
    Bhamidipati, Deepak
    Subbiah, Vivek
    TRENDS IN CANCER, 2023, 9 (10): : 828 - 839
  • [4] ALK fusions in the pan-cancer setting: another tumor-agnostic target?
    Aditya Shreenivas
    Filip Janku
    Mohamed A. Gouda
    Hui-Zi Chen
    Ben George
    Shumei Kato
    Razelle Kurzrock
    npj Precision Oncology, 7
  • [5] Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
    Hernandez, Susana
    Conde, Esther
    Molero, Aida
    Suarez-Gauthier, Ana
    Martinez, Rebeca
    Alonso, Marta
    Plaza, Carlos
    Camacho, Carmen
    Chantada, Debora
    Juaneda-Magdalena, Laura
    Garcia-Toro, Enrique
    Saiz-Lopez, Patricia
    Rojo, Federico
    Abad, Mar
    Boni, Valentina
    del Carmen, Sofia
    Regojo, Rita Maria
    Sanchez-Frias, Marina Esther
    Teixido, Cristina
    Paz-Ares, Luis
    Lopez-Rios, Fernando
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2024, 148 (03) : 318 - 326
  • [6] ALK fusions in the pan-cancer setting: another tumor-agnostic target?
    Shreenivas, Aditya
    Janku, Filip
    Gouda, Mohamed A.
    Chen, Hui-Zi
    George, Ben
    Kato, Shumei
    Kurzrock, Razelle
    NPJ PRECISION ONCOLOGY, 2023, 7 (01)
  • [7] Clinical Practice Guideline for tumor-agnostic treatment in patients with advanced solid tumors focus on DNA mismatch repair and tumor mutation burden
    Mishima, Saori
    ANNALS OF ONCOLOGY, 2022, 33 : S460 - S460
  • [8] Larotrectinib: A Novel Tumor-Agnostic Neurotrophic Tropomyosin Receptor Kinase (NTRK) Inhibitor in Advanced Solid Tumors
    Dhanushkodi, Manikandan
    Bajpai, Jyoti
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2021, 42 (03) : 279 - 281
  • [9] The analysis of BRAF fusions characteristics in Chinese solid tumor patients.
    Ma, Fang
    Zhao, Yaping
    Wang, Chenxi
    Han, Tiantian
    Ding, Ran
    Deng, Wanglong
    Bu, Fanfeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib
    Awada, Ahmad
    Berghmans, Thierry
    Clement, Paul M.
    Cuppens, Kristof
    De Wilde, Bram
    Machiels, Jean-Pascal
    Pauwels, Patrick
    Peeters, Marc
    Rottey, Sylvie
    Van Cutsem, Eric
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 169
12345